Medpace Holdings, Inc. (MEDP) Total Return CAGR:53.47%(TTM)
Over the latest trailing 12-month period, Medpace Holdings, Inc. (MEDP)'s total return cagr is +53.47%. The comparable SPY value is +26.21%. Year-to-date total return is -18.62%. Total return includes price appreciation and reinvested dividends.
Over longer horizons, Medpace Holdings, Inc.'s Total Return CAGR averages 27.22% over 3 years and 20.25% over 5 years. Total return includes dividends reinvested. The total return CAGR includes both price appreciation and dividends reinvested. This gives a more complete picture of Medpace Holdings, Inc.'s investment performance.
MEDP Total Return CAGR Chart
Medpace Holdings, Inc. (MEDP)
MEDP Quarterly Total Return (YoY)
Total Return Index growth vs the same quarter one year earlier, last 20 quarters.
MEDP Total Return CAGR History
| Year | Start Total Return | End Total Return | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2026 | 2021.05 | 1644.80 | -376.25 | -18.62% | -18.62% |
| 2025 | 1195.50 | 2021.05 | +825.55 | +69.05% | +69.05% |
| 2024 | 1103.02 | 1195.50 | +92.48 | +8.38% | +8.38% |
| 2023 | 764.34 | 1103.02 | +338.68 | +44.31% | +44.31% |
| 2022 | 783.16 | 764.34 | -18.82 | -2.40% | -2.40% |
| 2021 | 500.90 | 783.16 | +282.26 | +56.35% | +56.35% |
| 2020 | 302.48 | 500.90 | +198.42 | +65.60% | +65.60% |
| 2019 | 190.46 | 302.48 | +112.02 | +58.81% | +58.81% |
| 2018 | 130.48 | 190.46 | +59.99 | +45.97% | +45.97% |
| 2017 | 129.79 | 130.48 | +0.68 | +0.53% | +0.53% |
Quarterly Total Return: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q2 2026 | 1,645 | -4.8% | +45.6% |
| Q1 2026 | 1,728 | -15.8% | +53.7% |
| Q4 2025 | 2,051 | +13.8% | +71.0% |
| Q3 2025 | 1,802 | +59.5% | +50.0% |
| Q2 2025 | 1,129 | +0.5% | -22.6% |
| Q1 2025 | 1,124 | -6.3% | -22.4% |
| Q4 2024 | 1,199 | -0.1% | +7.3% |
| Q3 2024 | 1,201 | -17.6% | +35.5% |
| Q2 2024 | 1,459 | +0.6% | +72.5% |
| Q1 2024 | 1,449 | +29.7% | +118.7% |
| Q4 2023 | 1,118 | +26.1% | +46.2% |
| Q3 2023 | 887 | +4.9% | +56.8% |
| Q2 2023 | 845 | +27.6% | +57.8% |
| Q1 2023 | 663 | -13.3% | +12.6% |
| Q4 2022 | 764 | +35.1% | -3.0% |
| Q3 2022 | 566 | +5.6% | -17.0% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About Medpace Holdings, Inc.
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- August James Troendle